{{Rsnum
|rsid=1934951
|Gene=CYP2C8
|Chromosome=10
|position=96798548
|Orientation=minus
|GMAF=0.2787
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 1.8 | 28.3 | 69.9
| HCB | 14.6 | 50.4 | 35.0
| JPT | 19.5 | 50.4 | 30.1
| YRI | 16.3 | 42.9 | 40.8
| ASW | 7.1 | 37.5 | 55.4
| CHB | 14.6 | 50.4 | 35.0
| CHD | 11.0 | 50.5 | 38.5
| GIH | 13.9 | 34.7 | 51.5
| LWK | 7.3 | 46.4 | 46.4
| MEX | 1.7 | 31.0 | 67.2
| MKK | 9.7 | 34.8 | 55.5
| TSI | 1.0 | 30.4 | 68.6
| HapMapRevision=28
}}

{{PMID|18594024}} (T;T) associated with a higher risk of osteonecrosis of the jaw in am small study of multiple myeloma patients under bisphosphonate therapy

{{GWAS Summary
|SNP=rs1934951
|PubMedID=18594024
|Condition=Osteonecrosis of the jaw
|Gene=CYP2C8
|Risk Allele=T
|pValue=1.00E-006
|OR=12.75
|95CI=3.7-43.5
}}

{{omim
|desc=MYELOMA, MULTIPLE
|id=254500
|rsnum=1934951
}}

{{PharmGKB
|RSID=rs1934951
|Name_s=
|Gene_s=CYP2C8
|Feature=
|Evidence=PubMed ID:18594024
|Annotation=This variant was associated with bisphosphonate-related osteonecrosis of the jaw (ONJ) in a GWAS study. Individuals homozygous for the T allele had an increased risk for developing ONJ.
|Drugs=pamidronate; zoledronate
|Drug Classes=
|Diseases=Osteonecrosis
|Curation Level=Curated
|PharmGKB Accession ID=PA164926329
}}

{{PharmGKB
|RSID=rs1934951
|Name_s=
|Gene_s=CYP2C8
|Feature=
|Evidence=PubMed ID:18594024; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis (Initial Sample Size: 21 cases, 64 controls; Replication Sample Size: NR; Risk Allele: rs1934951-T). This variant is associated with Osteonecrosis of the jaw.
|Drugs=
|Drug Classes=
|Diseases=Osteonecrosis
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356406
}}
{{PMID Auto
|PMID=21151627
|Title=A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer
|OA=1
}}

{{PMID Auto
|PMID=21685474
|Title=CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma
|OA=1
}}

{{PMID Auto
|PMID=22339777
|Title=New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1934951
|overall_frequency_n=41
|overall_frequency_d=128
|overall_frequency=0.320312
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=35
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{PMID Auto
|PMID=23171856
|Title=Association between CYP2C8 (rs1934951) Polymorphism and Bisphosphonate-Related Osteonecrosis of the Jaws in Patients on Bisphosphonate Therapy: A Meta-Analysis
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Affy500k}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}